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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Brugada syndrome (BrS) is a hereditable sudden cardiac death (SCD).
Mutations in the SCN5A gene (the most common BrS-causing gene) are responsible for 20e25%
of this disease in Caucasian populations. However, the prevalence of SCN5A mutations
in patients with BrS in the Chinese Han population in Taiwan remains unknown. Therefore, in
this study, we investigated the prevalence of the SCN5A mutation in the largest BrS cohort in
Taiwan.
Methods: We consecutively enrolled 47 unrelated patients with BrS from medical centers and
hospitals in Taiwan between 2000 and 2010. Mutations within all the 27 translated exons, and
exoneintron boundaries of the SCN5A-encoded cardiac sodium channel were screened in all pa-
tients with BrS using direct sequencing. A total of 500 unrelated healthy volunteers with a
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Brugada syndrome with SCN5A mutations in Taiwan 621Results: SCN5A genetic variants were identified in 14 of the 47 patients with BrS and four of the
14 patients with BrS had missense mutations (1651 G>A, 1776 C>G, 3578 G>A). The prevalence
rate of SCN5A mutations was approximately 8% (4/47), which was significantly lower than that
reported in Caucasian populations (20e25%; pZ 0.0007). The average age of these 14 BrS pa-
tients with SCN5A variants at diagnosis (12 men and 2 women) was 40  13 years. Four patients
experienced SCD, and six presented with seizure or syncope. Only three patients (3/14, 21.4%)
had a family history of SCD.
Conclusion: The prevalence of SCN5Amutations in the Chinese Han population in Taiwanmay be
lower than that reported in the Caucasian populations. In addition, most patients with BrS did
not have a family history of SCD.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Brugada syndrome (BrS) is a sudden unexpected cardiac
death. In 1992, Brugada first described eight patients with a
history of sudden death and a distinct electrocardiogram
(ECG) pattern, consisting of right bundle branch block
(RBBB) with ST-segment elevation in the V1, V2, and V3
leads and a normal QT interval in the absence of any
structural heart disease.1 BrS is known to occur in 1e5/
10,000 inhabitants worldwide. Its frequency is lower in
Western countries and higher (5/10,000) in Southeast
Asia, especially in Thailand and the Philippines, where BrS
is considered to be the major cause of sudden death in
young individuals. In these countries, the syndrome is often
referred to as sudden unexplained nocturnal death syn-
drome.2,3 Results of epidemiologic studies suggest that the
disease might be responsible for nearly half of all the
sudden cardiac deaths (SCDs) in individuals without struc-
tural heart disease and that it is the most common cause of
SCD in young adults in South Asia.4,5
The clinical presentations of BrS are syncope, seizure,
and sudden death usually occurring early in the morning.
The life-threatening arrhythmia of BrS is usually ventricular
fibrillation (Vf) or polymorphic ventricular tachycardia
(VT).6 The average age at the time of initial diagnosis or
sudden death is 46  7 years, especially in men in our
previous report.7 This syndrome generally does not have
any prodromes and the patients usually do not have any
cardiovascular diseases.
In 1998, Chen et al first reported that BrS has a genetic
basis that is linked only to mutations in the sodium channel,
voltage-gated, type V, alpha subunit (SCN5A) gene, which
encodes the b-subunit of the sodium channel8 and has been
shown to be responsible for 20e25% of the disease in
Caucasian populations.9 It is a hereditary disease, having an
autosomal dominant inheritance pattern with incomplete
penetrance. Among the Asia countries, the disease has
been reported in Japan, Thailand, India, Laos, Vietnam,
Singapore, and Cambodia.10,11 Studies from Beijing, Nanj-
ing, Hangzhou, and Hong Kong showed that the prevalence
of SCN5A mutation in the Chinese Han population varied
from 0% to 25%.12e16 However, the percentage of SCN5A
mutations in patients with BrS in the Chinese Han popula-
tion in Taiwan remains unknown.
Since 2000, we have been continuously collecting in-
formation about the patients diagnosed with BrS at theNational Taiwan University Hospital (NTUH). In addition,
patients with BrS were referred from many medical centers
and hospitals in Taiwan for genetic screening for more than
10 years. With this support, we have collected the data on
most patients with BrS in Taiwan. In this study, using these
data, we report the unique clinical characteristics and
SCN5A genetic information of patients with BrS in this
largest cohort in Taiwan.
Methods
Study patients
From 2000 to 2010, we consecutively enrolled 47 unrelated
patients with BrS from medical centers and hospitals in
Taiwan. BrS was definitively diagnosed based on a
consensus report in 2005 when a Type 1 ST-segment
elevation (Brugada ECG) was observed in more than one
right precordial lead (V1eV3) in the presence or absence
of a sodium-channel blocking agent and in conjunction
with at least one of the following criteria: documented
Vf, polymorphic VT, a family history of SCD (<45 years
old), coved-type ECGs in family members, inducibility of
VT with programmed electrical stimulation, syncope, or
nocturnal agonal respirations.17e20 We collected basic
clinical information including age, sex, past history
(including syncope or sudden cardiac arrest), circumstances
surrounding these events (including sleeping, working,
resting, or exercise), and any prodromes or family history of
SCD (<45 years old). The study was approved by the local
ethical committee of NTUH, and all study patients provided
informed consent.
Genetic screening for SCN5A mutations
DNA extraction: After blood collection, samples were
immediately placed into tubes with ethylenediaminetetra-
acetic acid reagent and preserved in ice. The whole blood
samples were centrifuged at 2000 revolutions per minute
(rpm) for 10 minutes under 25C and three distinguishable
fractions were obtained. The buffy coat, which was located
in the intermediate layer, was drawn into another 15-mL
centrifuge tube for further isolation procedures using
Gentra Puregene Blood Kits (Qiagen, Hilden, Germany).
First, the red blood cell (RBC) lysis solution was added into
622 J.-M.J. Juang et al.the buffy coat to remove contaminants from the RBCs.
Subsequently, the samples were centrifuged at 3000 rpm
for 10 minutes and the supernatant liquids were discarded
to yield pure buffy coat without RBCs. Next, the cells were
mixed with cell lysis solution to induce chemical break-
down. The genomic DNA was obtained in the supernates
after centrifuging at 3000 rpm for 10 minutes. Finally, the
genomic DNA pellet was precipitated and washed using
isopropanol and ethanol solutions, respectively. After a dry
bath for 10 minutes, the DNA pellet was dissolved in
500e800 mL ddH2O.
Polymerase chain reaction and direct sequencing
The DNA obtained from patients with BrS was subjected to
polymerase chain reaction (PCR), which was performed in
thin-walled PCR tubes having a total volume of 25 L con-
taining 100 ng of genomic DNA, 0.12 mM of each primer,
100 mM deoxyribonucleotide triphosphates, 0.5 U of
AmpliTaq Gold (PE Applied Biosystems, Foster City, CA,
USA), and 2.5 L of GeneAmp 10 buffer II (10 mM Tris-HCl,
pH Z 8.3, 50 mM KCl) in 2 mM MgCl2 as provided by the
manufacturer. Amplification was performed in a multiblock
thermal cycler (Thermo Hybaid, Ashford, UK). PCR ampli-
fication was performed with an initial denaturation step at
95C for 10 minutes, followed by 35 cycles involving
denaturation at 94C for 30 seconds, primer annealing at
55C for 30 seconds, and an elongation step at 72C for 1
minute unless otherwise specified in the Electronic Sup-
plementary Material (S1). The final extension step was 72C
for 10 minutes. The primers were designed to cover the
entire coding region of the genes based on the information
in previous studies as well as the sequence data in Gen-
Bank. Multiple primer pairs were used for large exons. The
amplicons of SCN5A genes were sequenced with dye-
terminator cycle sequencing method (Perkin-Elmer, Foster
City, CA) on an automatic sequencing apparatus (ABI Prism
373A sequencer, Perkin-Elmer).21 Mutations or single
nucleotide polymorphisms (SNPs) within all 27 translated
exons, slice sites, and exoneintron boundaries of the
SCN5A-encoded cardiac sodium channel NaV1.5 were
detected using direct sequencing. Five hundred unrelated
and ostensibly healthy volunteers with no clinical cardiac
arrhythmias and with normal ECGs were genotyped as a
control group. Mutations were defined as rare, case-only
(absent in the 500 healthy volunteers enrolled from the
Chinese Han population in Taiwan) variants with amino acid
change that are possibly pathogenic. Variants with a minor
allele frequency >0.5% among the 500 healthy volunteers
in the Chinese Han population in Taiwan were termed as
SNPs.
Statistical analysis
All continuous data were expressed as mean  standard
deviation. A frequency comparison was performed using
the Chi-square test. Confidence intervals (CIs) of the
binominal distribution were calculated for the prevalence
rates. To compare the genetic effect of SCN5A SNP on BrS
patients with healthy controls, we analyzed the distribution
of allele and genotype frequencies in the two groups andcalculated the odds ratio (OR) using different inheritance
models including additive model, autosomal dominant
model, and autosomal recessive model. HardyeWeinberg
equilibrium of allele and genotype distribution of SCN5A
polymorphisms were tested using a Chi-square test. We
used logistic regression to calculate OR of increased risk for
BrS for each SNP. A two-tailed p < 0.05 was considered
significant.
Results
Clinical characteristics of BrS patients with SCN5A
genetic variants
SCN5A genetic variants were screened in all the 47 patients
with BrS who were enrolled, and 14 patients were identified
with SCN5A genetic variants. The clinical characteristics of
these 14 BrS patients with SCN5A genetic variants (12 men
and two women) are summarized in Table 1. The average
age at the time of syncope, seizure, or cardiac arrest was
40  13 years (range: 18e70 years). All of them had normal
physical examinations and none had significant biochemical
abnormalities that could be correlated with electrical
events. Cardiac catheterization and echocardiography of
these patients did not reveal any coronary artery disease or
obvious structural heart disease. Only three patients (21.4%)
had a positive family history of SCD. Four patients experi-
enced SCD, and six presented with seizure or syncope. The
circumstance of the index events was mostly resting (12/14,
86%) rather than sleeping. Ten patients had a spontaneously
Brugada-type I ECG and seven patients received implantable
cardioverter-defibrillator implantation.
Genetic variants of the SCN5A gene
Of the 14 BrS patients with SCN5A variants, four had ho-
mozygous missense mutations and 10 had heterozygous
nonsynonymous SNPs in the SCN5A gene, compared with the
genetic variants in the 500 unrelated controls without BrS.
The prevalence rate of SCN5A mutations was approximately
8% (4/47, 95% CI Z approximately 0.03e0.13). In total,
there were three different homozygous missense mutations
and two heterozygous nonsynonymous SNPs that resulted in
five different amino acid changes (Table 2). The homozy-
gous missense mutations (1651 G>A, 1776 C>G, 3578 G>A)
produced three different amino acid changes (Arg551Thr,
Asn592Lys, and Arg1193Gln) and were located in exons 12
and 20 of the SCN5A gene individually (Fig. 1). Four patients
with BrS had heterozygous functional SNPs in exon 12 (1673
A>G) that caused a fourth amino acid change (His558Arg)
and six patients with BrS had heterozygous nonsynonymous
SNPs in exon 18 (3269 C>T) that caused the fifth amino acid
change (Pro1090Leu) (Fig. 2). Interestingly, three BrS pa-
tients with a family history of SCD did not have an SCN5A
mutation or nonsynonymous SNPs. In contrast, four BrS
patients with SCN5Amutations did not have a family history
of SCD. A comparison of the prevalence of BrS patients with
SCN5A mutations in Caucasian populations with that in the
Chinese Han population in Taiwan showed that the preva-
lence of BrS patients with SCN5A mutations was signifi-
cantly lower (8.5% vs. 25%, p Z 0.0007) (Fig. 3).
Table 1 Clinical characteristics of 14 patients with Brugada syndrome and SCN5A genetic variants.
Patient
number
Sex Age at
diagnosis
(y)
Presentation Circumstance Documented
arrhythmias
Family
history
of SCD
Type of
SCN5A
variants
Type of
Brugada ECG
ICD
Treatment
1 M 47 Syncope/SCD Awake at rest Vf d Mutation Type I Yes
2 F 34 Syncope Awake at rest N/A d Mutation Type I No
3 M 34 Dizziness Awake at rest Inducible Vf d Mutation Type II Yes
4 M 48 Chest pain Awake at rest Inducible Vf d Mutation Type I Yes
5 M 36 Syncope Walking Vf Positive SNP Type I Yes
6 M 50 Seizure Sleeping N/A Positive SNP Type I Yes
7 F 24 Seizure Awake at rest VT Positive SNP Type I Yes
8 M 70 Near syncope Awake at rest N/A d SNP Type I No
9 M 18 Syncope Walking N/A d SNP Type II No
10 M 24 SCD Awake at rest N/A d SNP Type I No
11 M 38 Chest
tightness and
palpitation
Awake at rest N/A d SNP Type I No
12 M 44 SCD Having lunch VT d SNP Types I and II No
13 M 45 Syncope/
seizure/SCD
Sleeping Vf/VT d SNP Type I Yes
14 M 51 Chest
tightness with
hypotension
Having dinner N/A d SNP Type I No
ECG Z electrocardiogram; ICD Z implantable cardioverter-defibrillator; SCD Z sudden cardiac death; SNP Z single nucleotide poly-
morphism; Vf Z ventricular fibrillation; VT Z ventricular tachycardia.
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patients with BrS from different studies in the
Chinese Han population
We listed several studies on patients with BrS in Chinese
Han populations in Table 3.12e16 The patients with BrS
enrolled in these studies are all Chinese Han from northern
and southern China. The number of enrolled patients varied
from 7 to 50 (<15 patients in three studies). Two studies
enrolled symptomatic and asymptomatic patients with BrS,
whereas three only enrolled symptomatic patients with BrS.
The study from Hangzhou showed that five SNPs were
detected in 48 patients with BrS, but the prevalence rate of
SCN5A mutation was 0%, whereas the study from Hong Kong
revealed that the prevalence rate of SCN5A mutation was
14% (5 of 36 patients with BrS). After pooling all studies
together, the mean prevalence rate of SCN5A mutations in
146 patients with BrS in the Chinese Han population was
7.5% (range: 0e25%, 7.5  10.5%). The prevalence rate ofTable 2 Genetic results of Brugada syndrome patients with SCN
Number of unrelated
individuals
Region Nucleotide
changea
1 Exon 12 1651 G>A
4 Exon 12 1673 A>G
1 Exon 12 1776 C>G
6 Exon 18 3269 C>T
2 Exon 20 3578 G>A
D Z domain; SNP Z single nucleotide polymorphism.
a Relative to c: NM_00109405.1.SCN5Amutations in patients with BrS in Taiwan was close to
the average (8.5% vs. 7.5%).
Discussion
In 1992, Pedro and Josep Brugada originally described the
syndrome with a special ECG pattern consisting of an RBBB
and at least 1-mm ST segment elevation in leads V1eV3 in
association with SCD.1 Although BrS is prevalent worldwide
and the exact prevalence is changing overtime, it is more
common in Southeast Asian countries. In our previous study,
the prevalence rate of Brugada-type ECG in a hospital-
based population in Taiwan was 0.13%.22
BrS is generally considered to be a disorder in young
male adults, with arrhythmogenic manifestation first
occurring at an average age of 40 years. It typically occurs
with sudden death during sleeping.20 The male preference
(86%), mean age of diagnosis, and clinical presenting
symptoms of BrS in Taiwan were similar to those in5A variants.
Coding
effect
Location Type of variations
Ala551Thr DI/DII Missense mutation
His558Arg DI/DII SNP
Asn592Lys DI/DII Missense mutation
Pro1090Leu DII/DIII SNP
Arg1193Gln DII/DIII Missense mutation
Figure 1 DNA sequencing results of three missense muta-
tions identified on the SCN5A gene. (A) The arrows indicate two
nucleotide changes from GG to AA transition (homozygous ge-
notype) at position 1651 on exon 12 in a patient with Brugada
syndrome (BrS). (B) The arrows indicate two nucleotide
changes from CC to GG transition (homozygous genotype) at
position 1776 on exon 12 in a patient with BrS. (C) The arrows
indicate two nucleotide changes from GG to AA transition
(homozygous genotype) at position 3578 on exon 20 in two
patients with BrS.
Figure 2 DNA sequencing results of two single nucleotide
polymorphism identified on the SCN5A gene. (A) The arrows
(two spikes with different colors) indicate a nucleotide change
from AA to AG transition (heterozygous genotype) at position
1673 on exon 12 in four patients with Brugada syndrome (BrS).
(B) The arrows (two spikes with different colors) indicate a
nucleotide change from CC to CT transition (heterozygous ge-
notype) at position 3269 on exon 18 in six patients with BrS.
Figure 3 Significant difference in the prevalence of Brugada
syndrome (BrS) patients with SCN5A mutations between the
Chinese Han population in Taiwan and Caucasian populations.
624 J.-M.J. Juang et al.Caucasian populations. In contrast, the index event of BrS
in Taiwan occurred mostly when patients were awake at
rest rather than sleeping. Only two of the 14 patients with
BrS (14%) experienced the index event in the early
morning when they were sleeping. Although BrS is an
inheritable arrhythmic disease having an autosomal
dominant pattern with incomplete penetrance, only three
of the 14 BrS patients with SCN5A variants had a family
history of SCD. This implied that patients with BrS in
Taiwan have a preponderance of sporadic cases than that
of familial cases.
In 1998, Chen et al first reported that BrS has a genetic
basis that is linked only to mutations in SCN5A, the gene
that encodes the b-subunit of the sodium channel.8 After
more than 10 years, the SCN5A gene is still the most com-
mon BrS-causing gene and is responsible for 20e25% of this
disease in Caucasian populations and for as much as 40% in
cases of familial BrS.9,23 In 2011, the Heart Rhythm Society
(HRS) and the European Heart Rhythm Association (EHRA)
expert consensus statement described that comprehensive
SCN5A-targeted BrS genetic testing can be useful for any
patient in whom a cardiologist has established a clinical
index of suspicion for BrS based on examination of the pa-
tient’s clinical history, family history, and expressed elec-
trocardiographic (resting 12-lead ECGs and/or provocative
drug challenge testing) phenotype.23 However, the preva-
lence of SCN5A mutations in patients with BrS in the Chi-
nese Han population in Taiwan remains unknown. This is the
first study to report the result of SCN5A genetic testing for
BrS in the largest cohort in Taiwan. We found that the
prevalence of SCN5A mutations for BrS in the Chinese Han
population in Taiwan was less than half of that reported in
Caucasian populations (8% vs. 20e25%, p Z 0.0007), but
was close to the average prevalence of SCN5A mutations in
pooling 143 patients with BrS in the Chinese Han population
from several studies (8.5% vs. 7.5%, p Z 0.83).12e16 This
demonstrated that the ethnic difference plays an important
role on BrS and certainly affects the genetic results. It is
plausible that the SCN5A gene may not be the major BrS-
causing gene in the Chinese Han population as that is in
Caucasian populations.
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Brugada syndrome with SCN5A mutations in Taiwan 625Several characteristics of SCN5A mutations in our pa-
tients with BrS were different from those in other racial
populations. First, a retrospective analysis of BrS data-
bases showed that 293 mutations in SCN5A have been
described in association with BrS across most white and a
few nonwhite patients.24 We found three missense mu-
tations, including two novel mutations (A551T and
N592K), in our patients with BrS. Second, the four most
frequent BrS-associated mutations were E1784K,
F861WfsX90, D356N, and G1408R in the international
compendium of SCN5A mutations for BrS. However, we
did not detect any of them in our patients with BrS. Third,
of the 293 unique mutations, 208 (71%) localized to one of
the four transmembrane-spanning regions (DI, DII, DIII, or
DIV), 54 (18%) localized to an interdomain linker, 17 (6%)
localized to the C terminus, and 14 (5%) localized to the N
terminus. The three mutations and two nonsynonymous
SNPs we identified were interdomain linkers located in DI/
II or DII/III separately instead of transmembrane-spanning
regions.
Although several differences existed between the ge-
netic characteristics of SCN5A mutations in patients with
BrS in Taiwan and that in Caucasians populations, the two
populations were similar in some aspects. First, 225 (77%)
of the 293 mutations reported worldwide were identified
only once. The two novel mutations we found were also
identified once in our patients with BrS. In addition, of the
438 SCN5A mutation-positive cases, only 13 (3%) harbored
multiple mutations. In addition, in our study, none of the
patients with BrS had multiple SCN5A mutations. The ge-
netic results demonstrated that single point mutation was
the main genetic presentation in BrS in both Caucasian and
Asian populations.
In this study, we found that 10 patients with BrS have
nonsynonymous SNPs (1673 A>G or 3269 C>T) in the SCN5A
gene. We found that 1673 A>G SNP was not significantly
associated with an increased risk of BrS among the different
inheritance models of analyses (OR Z 1.9, p Z 0.23 in
additive model; OR Z 2.3, p Z 0.17 in the autosomal
dominant model), whereas 3269 C>T SNP was significantly
associated with BrS (OR Z 18, p < 0.001) in both the ad-
ditive and autosomal dominant model. The results sug-
gested that patients with BrS in Taiwan are more likely to
have the 3269 C>T SNP rather than 1673 A>G SNP
compared with healthy controls (Supplementary Tables 1
and 2). This 3269 C>T SNP requires further functional
studies.
In conclusion, compared with Caucasian populations, the
patients with BrS in Taiwan had some different clinical
characteristics and low prevalence of SCN5A mutations. In
2011, the HRS and EHRA expert consensus statement
announced that mutation-specific genetic testing is rec-
ommended for family members and appropriate relatives
following the identification of the BrS-causative mutation in
an index case. Given that SCN5A remains the most common
BrS genotype despite accounting for 8% of BrS in Taiwan,
genetic heterogeneity of the disease is evident. Recently,
10 minor BrS-susceptibility genes (GPD1L, CACNA1C,
CACNB2B, CACNA2D1, SCN1B, SCN3B, MOG1, KCND3,
KCNE3, and KCNE5) were discovered25 and should be
screened for in Chinese Han patients with BrS but without
SCN5A genetic variants.
626 J.-M.J. Juang et al.Limitations
The first limitation is that although this is the largest cohort
of patients with BrS in Taiwan, some patients in other
hospitals were not referred for genetic tests because of
family matters or inconvenient accesses to our genetic core
laboratory. However, BrS is a rare genetic disease.
Approximately, three-fourth of patients with BrS in this
cohort was referred from other medical centers or hospitals
in Taiwan in the past 10 years. With the support, this cohort
has become the largest referral cohort of patients with BrS
in Taiwan. In addition, the geographic distributions of the
referred patients with BrS were from the north, south,
east, and west of Taiwan. As a result, this BrS cohort may
represent the domestic genetic pattern of BrS in Taiwan.
The study result could be an important genetic reference
for BrS in Taiwan. The second limitation is that we did not
screen microstructural DNA variants such as copy number
variations on the SCN5A gene that warrant further studies.
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